Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment

被引：0
|
作者：
Rexer, H. [1 ,3 ]
Ohlmann, C. -H. [2 ]
Grimm, M. -O.
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Deutsch Krebsgesellschaft eV, Arbeitsgemeinschaft Urol Onkol, Berlin, Germany
[3] AUO Geschaftsstelle Frau Heidrun Rexer ViSdP, MeckEvidence H Rexer Seestr 11, D-17252 Schwarz, Germany
来源：
UROLOGIE | 2023年 / 62卷 / 03期
关键词：
D O I：
10.1007/s00120-023-02056-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 339
页数：2
相关论文
共 50 条
  • [1] Combination Therapy for High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) with and without BCG Pretreatment
    Rexer, Heidrun
    Grimm, Marc-Oliver
    Ohlmann, Carsten-H.
    AKTUELLE UROLOGIE, 2024, 55 (05) : 412 - 413
  • [2] Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.
    Gotto, Geoffrey T.
    Alimohamed, Nimira S.
    Kulkarni, Girish S.
    Black, Peter C.
    Kassouf, Wassim
    Sridhar, Srikala S.
    Kokorovic, Andrea
    Eigl, Bernhard J.
    Blais, Normand
    Lalani, Aly-Khan A.
    Osborne, Brendan J. W.
    Wallis, Christopher J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] DRIVERS OF TREATMENT PREFERENCES IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) PATIENTS: QUALITATIVE INTERVIEWS TO INFORM A PATIENT-PREFERENCE STUDY
    Mason, B.
    Eccleston, A.
    Gater, A.
    Hauber, B.
    Thompson, A.
    Coulter, J.
    Guy, M.
    Nunes, Ayala L.
    Brinkmann, J.
    Hallworth, P.
    Cappelleri, J.
    Bell, B.
    Chang, J.
    Satkunasivam, R.
    VALUE IN HEALTH, 2023, 26 (12) : S494 - S495
  • [4] Tumor mutational burden (TMB) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).
    Bastos, Diogo Assed
    Lima, Mariana
    Mattedi, Romulo Loss
    dos Santos, Filipe Ferreira
    Buzatto, Vanessa
    Barreiro, Rodrigo
    Ribeiro-Filho, Leopoldo
    Cordeiro, Mauricio
    Amano, Mariane
    Souza, Jussara Michaloski
    Bettoni, Fabiana
    Favoretto Galante, Pedro Alexandre
    Dzik, Carlos
    Nahas, William Carlos
    Camargo, Anamaria Aranha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
    Musat, Mihaela Georgiana
    Kwon, Christina Soeun
    Masters, Elizabeth
    Sikirica, Slaven
    Pijush, Debduth B.
    Forsythe, Anna
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 35 - 48
  • [6] Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG
    Khattak, Aimal Alam
    Javed, Ahmed
    Pokhrel, Prakriti
    Mukhtar, Sameen
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (02): : 457 - 459
  • [7] [18F]-FDG PET/CT FOR BLADDER CANCER STAGING AND DECISION-MAKING IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC)
    Hurle, Rodolfo
    Casale, Paolo
    Saita, Alberto
    Buffi, NicoloMaria
    Lughezzani, Giovanni
    Contieri, Roberto
    Fasulo, Vittorio
    Frego, Nicola
    Benetti, Alessio
    Chiti, Arturo
    Rodari, Marcello
    Sollini, Martini
    Pini, Cristiano
    Gelardi, Fabrizia
    Guazzoni, Giorgio
    Lazzeri, Massimo
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1010 - E1010
  • [8] [18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
    Hurle, R.
    Gobbo, A.
    Casale, P.
    Saita, A.
    Buffi, N.
    Lughezzani, G.
    Sollini, M.
    Rodari, M.
    Pini, C.
    Gelardi, F.
    Contieri, R.
    Guazzoni, G.
    Chiti, A.
    Lazzeri, M.
    EUROPEAN UROLOGY, 2022, 81 : S358 - S359
  • [9] Combination Therapy for Patients with High-risk non-muscle invasive Bladder Cancer (HR-NMIBC) A randomized, open-label, multi-center, world-wide, Phase III Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as a Combination Therapy compared to BCG alone in Patients with High-risk non-muscle invasive Bladder Cancer (POTOMAC) - AB 69/18 of the AUO
    Rexer, H.
    Merseburger, A.
    Boegemann, M.
    AKTUELLE UROLOGIE, 2019, 50 (04) : 345 - 346
  • [10] Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists
    Moussa, Mohamad
    Chakra, Mohamad Abou
    Shore, Neal D.
    Papatsoris, Athanasios
    Farahat, Yasser
    ODonnell, Michael A.
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2024, 96 (01)
12345